Shikonin inhibits oxidized LDL-induced monocyte adhesion by suppressing NFκB activation via up-regulation of PI3K/Akt/Nrf2-dependent antioxidation in EA.hy926 endothelial cells

Biochem Pharmacol. 2015 Feb 1;93(3):352-61. doi: 10.1016/j.bcp.2014.12.005. Epub 2014 Dec 23.

Abstract

Oxidized low-density lipoprotein (oxLDL) is a key contributor to atherogenesis through multiple mechanisms, including the reactive oxygen species (ROS)-mediated nuclear factor-kappaB (NFκB) signaling pathway. Although shikonin, one of the main active components isolated from the Chinese herb Lithospermum erythrorhizon, has been shown to possess cardioprotective, antioxidative, and anti-inflammatory effects, the mechanisms underlying these actions are not well understood. In this study, we used EA.hy926 endothelial-like cells to examine the anti-atherogenic activity of shikonin. Shikonin (0-1 μM) concentration-dependently induced heme oxygenase-1, glutamate cysteine ligase modifier subunit, catalase, superoxide dismutase 1, glutathione peroxidase 1, and glutathione reductase protein and mRNA expression and glutathione content via activation of the phosphatidylinositol 3-kinase (PI3K)/Akt/Nrf2 signaling pathway. In the presence of oxLDL (40 μg/ml), shikonin pretreatment reversed oxLDL-induced ROS production, antioxidant response element reporter activity, NFκB nuclear translocation, and intercellular adhesion molecule (ICAM)-1 and E-selectin expression and suppressed the increase of monocyte adhesion to endothelial cells. Nrf2 knockdown by using RNA interference attenuated the ability of shikonin to inhibit oxLDL-induced NFκB DNA binding activity, adhesion molecule expression, and monocyte adhesion. Taken together, these results suggest that shikonin protects against oxLDL-induced endothelial damage by suppressing ROS/NFκB-mediated ICAM-1 and E-selectin expression via up-regulation of PI3K/Akt/Nrf2-dependent antioxidant enzyme expression.

Keywords: Adhesion molecules; Antioxidant defense; Nuclear factor erythroid 2-related factor 2 (Nrf2); Nuclear factor-kappaB (NFκB); Oxidized LDL; Shikonin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antioxidants / pharmacology
  • Cell Adhesion / drug effects
  • Cell Adhesion / physiology*
  • Cell Line, Tumor
  • Dose-Response Relationship, Drug
  • Endothelial Cells / drug effects
  • Endothelial Cells / metabolism
  • Human Umbilical Vein Endothelial Cells / drug effects
  • Human Umbilical Vein Endothelial Cells / metabolism
  • Humans
  • Lipoproteins, LDL / antagonists & inhibitors
  • Lipoproteins, LDL / toxicity*
  • Monocytes / drug effects
  • Monocytes / metabolism
  • NF-E2-Related Factor 2 / biosynthesis*
  • NF-kappa B / antagonists & inhibitors
  • NF-kappa B / metabolism*
  • Naphthoquinones / pharmacology*
  • Phosphatidylinositol 3-Kinase / biosynthesis*
  • Proto-Oncogene Proteins c-akt / biosynthesis*
  • Up-Regulation / drug effects
  • Up-Regulation / physiology

Substances

  • Antioxidants
  • Lipoproteins, LDL
  • NF-E2-Related Factor 2
  • NF-kappa B
  • NFE2L2 protein, human
  • Naphthoquinones
  • oxidized low density lipoprotein
  • shikonin
  • Phosphatidylinositol 3-Kinase
  • Proto-Oncogene Proteins c-akt